Cryo-Cell International (NYSEAMERICAN:CCEL) Share Price Passes Above 50 Day Moving Average – Time to Sell?

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL)’s share price passed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $3.57 and traded as high as $3.79. Cryo-Cell International shares last traded at $3.79, with a volume of 659 shares.

Cryo-Cell International Price Performance

The stock has a fifty day moving average price of $3.57 and a two-hundred day moving average price of $3.49. The company has a market cap of $30.55 million, a P/E ratio of -11.48 and a beta of 0.48.

Cryo-Cell International (NYSEAMERICAN:CCEL) last announced its earnings results on Tuesday, April 14th. The company reported $0.01 earnings per share (EPS) for the quarter. The company had revenue of $7.68 million for the quarter.

Hedge Funds Weigh In On Cryo-Cell International

An institutional investor recently bought a new stake in Cryo-Cell International stock. Susquehanna International Group LLP acquired a new position in shares of Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned about 0.14% of Cryo-Cell International at the end of the most recent reporting period. 10.44% of the stock is owned by institutional investors and hedge funds.

Cryo-Cell International Company Profile

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.